Raleigh biotech developing therapeutics for migraine and other headache disorders. Lead program SLTE-1009 is a subcutaneous anti-PACAP monoclonal antibody in-licensed from DartsBio Pharmaceuticals, targeting a pathway distinct from CGRP.
At a glance
- HQ: Raleigh
- Sector: Biotech
- Stage: Series A
- Total raised: $130M
- Last round: Series A
The rest of this record is behind a free account.
Founders, funding history, investor connections, and recent signals load on this page as soon as you sign in. Accounts open immediately, and I read every signup.